GXIN Stock Chart & Stats
$517.42
$0.00(0.00%)
At close: 4:00 PM EDT
$517.42
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$347.84 - $1,649.75
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
$19.00B
Enterprise Value$3.53K
Total Cash (Recent Filing)$176.21M
Total Debt (Recent Filing)$1.60B
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Oct 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.28
Shares Outstanding34,540,000
10 Day Avg. Volume0
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.40
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$596.91Price Target Upside15.36% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)37.29
Revenue Forecast (FY)$46.96B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From Regulated Drug PackagingGerresheimer’s core business sells primary pharmaceutical packaging and drug-delivery systems under long qualification cycles and repeat purchase patterns. Regulatory barriers and customer qualification create durable, recurring revenue streams that sustain volumes and customer stickiness over years.
Sustained Top-line GrowthConsistent revenue expansion over multiple years demonstrates expanding market penetration and scale in pharma packaging. Steady top-line growth provides capacity to invest in capabilities, absorb cyclicality, and potentially restore margins once operational issues are addressed.
Positive And Stable Operating Cash FlowStable operating cash generation underpins operational resilience despite accounting losses. Positive OCF supports ongoing working-capital needs, funds some investment without immediate equity raises, and provides a foundation for deleveraging if management prioritizes cash conversion.
Bears Say
Sharp Swing To Operating LossesA sudden move from multi-year profitability to substantial operating and net losses materially weakens earnings power. It reduces internal funding capacity, pressures margins, and raises execution risk if the drivers (costs, impairments, or one-offs) are structural rather than temporary.
Rising Leverage And Weaker Equity BaseHigher debt alongside a falling equity base increases financial risk and reduces flexibility. Elevated leverage raises refinancing and interest-rate vulnerability, constraining ability to fund investments, respond to shocks, or pursue strategic M&A without external costlier financing.
Deeply Negative Free Cash FlowPersistent and large negative FCF despite positive operating cash flow suggests heavy capex, working-capital strain, or other cash drains. This cash burn forces reliance on external financing, complicates debt reduction, and leaves less room to rebuild margins or return capital to shareholders.
Gerresheimer News
GXIN FAQ
What was Gerresheimer AG’s price range in the past 12 months?
Gerresheimer AG lowest stock price was $347.84 and its highest was $1649.75 in the past 12 months.
What is Gerresheimer AG’s market cap?
Gerresheimer AG’s market cap is $19.00B.
When is Gerresheimer AG’s upcoming earnings report date?
Gerresheimer AG’s upcoming earnings report date is Oct 01, 2026 which is in 57 days.
How were Gerresheimer AG’s earnings last quarter?
Gerresheimer AG released its earnings results on Jul 30, 2026. The company reported $6.367 earnings per share for the quarter, beating the consensus estimate of $5.52 by $0.847.
Is Gerresheimer AG overvalued?
According to Wall Street analysts Gerresheimer AG’s price is currently Undervalued.
Does Gerresheimer AG pay dividends?
Gerresheimer AG does not currently pay dividends.
What is Gerresheimer AG’s EPS estimate?
Gerresheimer AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gerresheimer AG have?
Gerresheimer AG has 34,540,000 shares outstanding.
What happened to Gerresheimer AG’s price movement after its last earnings report?
Gerresheimer AG reported an EPS of $6.367 in its last earnings report, beating expectations of $5.52. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gerresheimer AG?
Currently, no hedge funds are holding shares in MX:GXIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gerresheimer Stock Smart Score
Company Description
Gerresheimer AG
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. Its Plastics & Devices segment provides a variety of drug administration tools, such as inhalers, insulin pen systems, prefillable syringes, and diagnostic systems, for the pharmaceutical, biotech, diagnostics, and medical technology sectors. This division also manufactures plastic containers, closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and related accessories for solid, liquid, and ophthalmic applications, alongside bottles for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging products for the pharmaceutical and cosmetics industries, including infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; and miniature bottles for liquid food, spices, spirits, fragrances, deodorants, skincare, and wellness products. Lastly, the Advanced Technologies division focuses on developing intelligent drug delivery systems, like micro pumps, designed to enable the self-administration of medication for conditions such as Parkinson's disease or heart failure, serving its pharmaceutical and biotech clients.
GXIN Stock 12 Month Forecast
Average Price Target
$596.91
▲(15.36% Upside)